These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28786057)

  • 41. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
    Chen SH; Chow JM; Hsieh YY; Lin CY; Hsu KW; Hsieh WS; Chi WM; Shabangu BM; Lee CH
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071955
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
    Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.
    Park J; Kim S; Oh JK; Kim JY; Yoon SS; Lee D; Kim Y
    J Biochem Mol Biol; 2005 Nov; 38(6):725-38. PubMed ID: 16336789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
    Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
    Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib.
    Synowiec E; Hoser G; Wojcik K; Pawlowska E; Skorski T; Błasiak J
    Int J Mol Sci; 2015 Aug; 16(8):18111-28. PubMed ID: 26251899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells.
    García-Alegría E; Lafita-Navarro MC; Aguado R; García-Gutiérrez L; Sarnataro K; Ruiz-Herguido C; Martín F; Bigas A; Canelles M; León J
    Cancer Lett; 2016 May; 375(1):92-99. PubMed ID: 26944313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
    Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P
    Haematologica; 2007 Jun; 92(6):838-41. PubMed ID: 17550858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.
    Li W; Ji M; Lu F; Pang Y; Dong X; Zhang J; Li P; Ye J; Zang S; Ma D; Ji C
    Cell Death Dis; 2018 Aug; 9(9):855. PubMed ID: 30154435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
    Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
    Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
    Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
    Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
    Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of cryptotanshinone on imatinib sensitivity and P-glycoprotein expression of chronic myeloid leukemia cells].
    Ge YQ; Cheng RB; Yang B; Huang Z; Chen Z
    Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2389-95. PubMed ID: 26591531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
    Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
    Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
    Liao HC; Chou YJ; Lin CC; Liu SH; Oswita A; Huang YL; Wang YL; Syu JL; Sun CM; Leu CM; Lin CH; Fu SL
    Biochem Pharmacol; 2019 May; 163():308-320. PubMed ID: 30822403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib.
    Lompardía SL; Díaz M; Papademetrio DL; Mascaró M; Pibuel M; Álvarez E; Hajos SE
    Glycobiology; 2016 Apr; 26(4):343-52. PubMed ID: 26582603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.